Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion

被引:152
作者
Sethi, Sanjeev [2 ]
Nester, Carla M. [1 ,3 ,4 ]
Smith, Richard J. H. [1 ,3 ,4 ]
机构
[1] Univ Iowa, Dept Internal Med, Div Nephrol, Carver Coll Med, Iowa City, IA 52242 USA
[2] Mayo Clin, Div Anat Pathol, Dept Lab Med & Pathol, Rochester, MN USA
[3] Carver Coll Med, Mol Otolaryngol & Renal Res Labs, Iowa City, IA USA
[4] Univ Iowa, Dept Pediat, Div Nephrol, Carver Coll Med, Iowa City, IA 52242 USA
关键词
complement; glomerular disease; immunology; membrano-proliferative glomerulonephritis (MPGN); pathology; DENSE DEPOSIT DISEASE; FACTOR-H; ALTERNATIVE PATHWAY; MUTATION; REVEALS; PROTEIN;
D O I
10.1038/ki.2011.399
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Membranoproliferative glomerulonephritis (MPGN) denotes a general pattern of glomerular injury that is easily recognized by light microscopy. With additional studies, MPGN subgrouping is possible. For example, electron microscopy resolves differences in electron-dense deposition that are classically referred to as MPGN type I (MPGN I), MPGN II, and MPGN III, while immunofluorescence typically detects immunoglobulins in MPGN I and MPGN III but not in MPGN II. All three MPGN types stain positive for complement component 3 (C3). Subgrouping has led to unnecessary confusion, primarily because immunoglobulin-negative MPGN I and MPGN III are more common than once recognized. Together with MPGN II, which is now called dense deposit disease, immunoglobulin-negative, C3-positive glomerular diseases fall under the umbrella of C3 glomerulopathies (C3G). The evaluation of immunoglobulin-positive MPGN should focus on identifying the underlying trigger driving the chronic antigenemia or circulating immune complexes in order to begin disease-specific treatment. The evaluation of C3G, in contrast, should focus on the complement cascade, as dysregulation of the alternative pathway and terminal complement cascade underlies pathogenesis. Although there are no disease-specific treatments currently available for C3G, a better understanding of their pathogenesis would set the stage for the possible use of anti-complement drugs. Kidney International (2012) 81, 434-441; doi:10.1038/ki.2011.399; published online 7 December 2011
引用
收藏
页码:434 / 441
页数:8
相关论文
共 29 条
[21]   Production of biologically active complement factor H in therapeutically useful quantities [J].
Schmidt, Christoph Q. ;
Slingsby, Fern C. ;
Richards, Anna ;
Barlow, Paul N. .
PROTEIN EXPRESSION AND PURIFICATION, 2011, 76 (02) :254-263
[22]   Primary glomerulonephritis with isolated C3 deposits:: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome [J].
Servais, Aude ;
Fremeaux-Bacchi, Veronique ;
Lequintrec, Moglie ;
Salomon, Remi ;
Blouin, Jacques ;
Knebelmann, Bertrand ;
Grunfeld, Jean-Pierre ;
Lesavre, Philippe ;
Noel, Laure-Helene ;
Fakhouri, Fadi .
JOURNAL OF MEDICAL GENETICS, 2007, 44 (03) :193-199
[23]   Proliferative Glomerulonephritis Secondary to Dysfunction of the Alternative Pathway of Complement [J].
Sethi, Sanjeev ;
Fervenza, Fernando C. ;
Zhang, Yuzhou ;
Nasr, Samih H. ;
Leung, Nelson ;
Vrana, Julie ;
Cramer, Carl ;
Nesteri, Carla M. ;
Smith, Richard. H. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (05) :1009-1017
[24]   Membranoproliferative Glomerulonephritis Secondary to Monoclonal Gammopathy [J].
Sethi, Sanjeev ;
Zand, Ladan ;
Leung, Nelson ;
Smith, Richard J. H. ;
Jevremonic, Dragan ;
Herrmann, Sandra S. ;
Fervenza, Fernando C. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (05) :770-782
[25]   New approaches to the treatment of dense deposit disease [J].
Smith, Richard J. H. ;
Alexander, Jessy ;
Barlow, Paul N. ;
Botto, Marina ;
Cassavant, Thomas L. ;
Cook, H. Terence ;
de Cordoba, Santiago Rodriguez ;
Hageman, Gregory S. ;
Jokiranta, T. Sakari ;
Kimberling, William J. ;
Lambris, John D. ;
Lanning, Lynne D. ;
Levidiotis, Vicki ;
Licht, Christoph ;
Lutz, Hans U. ;
Meri, Seppo ;
Pickering, Matthew C. ;
Quigg, Richard J. ;
Rops, Angelique L. ;
Salant, David J. ;
Sethi, Sanjeev ;
Thurman, Joshua M. ;
Tully, Hope F. ;
Tully, Sean P. ;
van der Vlag, Johan ;
Walker, Patrick D. ;
Wuerzner, Reinhard ;
Zipfel, Peter F. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (09) :2447-2456
[26]   Dense deposit disease [J].
Smith, Richard J. H. ;
Harris, Claire L. ;
Pickering, Matthew C. .
MOLECULAR IMMUNOLOGY, 2011, 48 (14) :1604-1610
[27]  
STRIFE CF, 1977, CLIN NEPHROL, V7, P65
[28]   MODULATION OF ALTERNATIVE COMPLEMENT PATHWAY BY BETA-1H GLOBULIN [J].
WHALEY, K ;
RUDDY, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 1976, 144 (05) :1147-1163
[29]   Complement regulators and inhibitory proteins [J].
Zipfel, Peter F. ;
Skerka, Christine .
NATURE REVIEWS IMMUNOLOGY, 2009, 9 (10) :729-740